摘要
AIM:To compare the efficacy and safety of paclitaxel combined with fluorouracil plus cisplatin(PCF),and oxaliplatin combined with fluorouracil plus leucovorin(FOLFOX-4) regimens for advanced gastric cancer(AGC).METHODS:Ninety-four patients with AGC were randomly assigned to receive paclitaxel(50 mg/m2 iv) on days 1,8 and 15,cisplatin(20 mg/m2 iv) and ? uorouracil(750 mg/m2 iv) on days 1-5,or oxaliplatin(85 mg/m2 iv) and leucovorin(200 mg/m2 iv) on day 1,followed by bolus fluorouracil(400 mg/m2 iv) and fluorouracil(600 mg/m2 iv) on days 1 and 2.The primary end point was the 1-year survival time.RESULTS:The overall response rate(ORR) of the pa-tients was 48.0% and 45.5% to PCF and FOLFOX-4,respectively.The disease control rate(DCR) of PCF and FOLFOX-4 was 82.0% and 81.8%,respectively.The median survival times(MSTs) of the patients were 10.8 and 9.9 mo,respectively,after treatment with PCF and FOLFOX-4.The 1-year survival rate of the patients was 36.0% and 34.1%,respectively,after treatment with PCF and FOLFOX-4.No significant difference was observed in ORR,DCR,MST or 1-year survival rate between the two groups.The most common adverse events were anemia,nausea and vomiting,and grade 3/4 alopecia in PCF treatment group,and anemia,grade 1/2 neurotoxic effect and grade 3/4 neutropenia in FOLFOX-4 treatment group.CONCLUSION:Patients with AGC have a similar response rate to PCF and FOLFOX-4 regimens with a similar survival rate.The PCF and FOLFOX-4 regimens are efficacious and tolerable as a promising therapy for AGC.
AIM：To compare the efficacy and safety of paclitaxel combined with fluorouracil plus cisplatin（PCF）,and oxaliplatin combined with fluorouracil plus leucovorin（FOLFOX-4） regimens for advanced gastric cancer（AGC）.METHODS：Ninety-four patients with AGC were randomly assigned to receive paclitaxel（50 mg/m2 iv） on days 1,8 and 15,cisplatin（20 mg/m2 iv） and ？ uorouracil（750 mg/m2 iv） on days 1-5,or oxaliplatin（85 mg/m2 iv） and leucovorin（200 mg/m2 iv） on day 1,followed by bolus fluorouracil（400 mg/m2 iv） and fluorouracil（600 mg/m2 iv） on days 1 and 2.The primary end point was the 1-year survival time.RESULTS：The overall response rate（ORR） of the pa-tients was 48.0% and 45.5% to PCF and FOLFOX-4,respectively.The disease control rate（DCR） of PCF and FOLFOX-4 was 82.0% and 81.8%,respectively.The median survival times（MSTs） of the patients were 10.8 and 9.9 mo,respectively,after treatment with PCF and FOLFOX-4.The 1-year survival rate of the patients was 36.0% and 34.1%,respectively,after treatment with PCF and FOLFOX-4.No significant difference was observed in ORR,DCR,MST or 1-year survival rate between the two groups.The most common adverse events were anemia,nausea and vomiting,and grade 3/4 alopecia in PCF treatment group,and anemia,grade 1/2 neurotoxic effect and grade 3/4 neutropenia in FOLFOX-4 treatment group.CONCLUSION：Patients with AGC have a similar response rate to PCF and FOLFOX-4 regimens with a similar survival rate.The PCF and FOLFOX-4 regimens are efficacious and tolerable as a promising therapy for AGC.
基金
Supported by The National Natural Science Foundation of China, No. 30872176, 30950022 and 30972703
Jiangsu Province of China, No. K200403
Department of Public Health and Department of Science and Technology (BS2005616)
